{
  "source": "PA-Notification-SLIT.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1133-12\nProgram Prior Authorization/Notification\nMedication Sublingual Immunotherapy (SLIT) – Grastek (Timothy grass pollen\nallergen extract), Odactra (Dermatophagoides farinae/Dermatophagoides\npteronyssinus allergen extract), Oralair (Sweet Vernal, Orchard, Perennial\nRye, Timothy, and Kentucky Blue Grass Mixed Pollens allergen extract),\nRagwitek (Short Ragweed Pollen allergen extract)\nP&T Approval Date 5/2014, 5/2015, 4/2016, 4/2017, 3/2018, 3/2019, 3/2020, 3/2021, 3/2022,\n3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nThe sublingual immunotherapy (SLIT) medications are indicated for patients who have\nsymptoms of allergic rhinitis with natural exposure to allergens and who demonstrate specific\nIgE antibodies to the relevant allergen. Grastek (Timothy grass pollen allergen extract) and\nOralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed\nPollens allergen extract) are indicated for patients with grass pollen-induced allergic rhinitis,\nRagwitek (short ragweed pollen allergen extract) is indicated for ragweed pollen-induced\nallergic rhinitis and Odactra (Dermatophagoides farinae/Dermatophagoides pteronyssinus\nallergen extract), is indicated for house dust mite (HDM)-induced allergic rhinitis.\nCandidates for immunotherapy are patients whose symptoms are not adequately controlled by\nmedications, and avoidance measures have been ineffective. In addition, patients experiencing\nunacceptable adverse effects of medications or who wish to reduce the long-term use of\nmedications may also be candidates for immunotherapy.\n2. Coverage Criteriaa:\nA. Grastek\n1. Initial Authorization\na. Grastek will be approved based on all of the following:\n(1) Diagnosis of grass pollen-induced allergic rhinitis\n-AND-\n(2) Diagnosis confirmed by one of the following:\n(a) Positive skin test to Timothy grass or cross-reactive grass pollens (e.g., Sweet\nVernal, Orchard/Cocksfoot, Pe",
    "llen-induced allergic rhinitis\n-AND-\n(2) Diagnosis confirmed by one of the following:\n(a) Positive skin test to Timothy grass or cross-reactive grass pollens (e.g., Sweet\nVernal, Orchard/Cocksfoot, Perennial Rye, Kentucky Blue/June grass,\nMeadow Fescue, or Redtop)\n(b) in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-\nreactive grass pollens (e.g., Sweet Vernal, Orchard/Cocksfoot, Perennial Rye,\nKentucky Blue/June grass, Meadow Fescue, or Redtop)\n© 2025 UnitedHealthcare Services Inc.\n1\n-AND-\n(3) Treatment is started or will be started at least 12 weeks before the expected onset\nof the grass pollen season\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Grastek will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Grastek therapy\nAuthorization will be issued for 12 months.\nB. Oralair\n1. Initial Authorization\na. Oralair will be approved based on all of the following:\n(1) Diagnosis of grass pollen-induced allergic rhinitis\n-AND-\n(2) Diagnosis confirmed by one of the following:\n(a) Positive skin test to any of the five grass species [(i.e., Sweet Vernal, Orchard,\nPerennial Rye, Timothy, and Kentucky Blue grass mixed pollens) or cross\nreactive grass pollens (e.g., Cocksfoot, Meadow Fescue, or Redtop)].\n(b) in vitro testing for pollen-specific IgE antibodies to any of the five grass\nspecies [(i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky\nBlue grass mixed pollens) or cross reactive grass pollens (e.g., Cocksfoot,\nMeadow Fescue, or Redtop)].\n-AND-\n(3) Treatment is started or will be started at least 4 months before the expected onset\nof the grass pollen season\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Oralair will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Oralair therapy\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services Inc.\n2\nC. Ragwitek\n1. Initial Authoriza",
    "owing criterion:\n(1) Documentation of positive clinical response to Oralair therapy\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services Inc.\n2\nC. Ragwitek\n1. Initial Authorization\na. Ragwitek will be approved based on all of the following:\n(1) Diagnosis of short ragweed pollen-induced allergic rhinitis\n-AND-\n(2) Diagnosis confirmed by one of the following:\n(a) Positive skin test to short ragweed pollen\n(b) in vitro testing for pollen-specific IgE antibodies for short ragweed pollen\n-AND-\n(3) Treatment is started or will be started at least 12 weeks before the expected onset\nof the short ragweed pollen season\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ragwitek will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Ragwitek therapy\nAuthorization will be issued for 12 months.\nD. Odactra\n1. Initial Authorization\na. Odactra will be approved based on both of the following:\n(1) Diagnosis of house dust mite (HDM)-induced allergic rhinitis.\n-AND-\n(2) Diagnosis confirmed by one of the following:\n(a) Positive skin test to licensed house dust mite allergen extracts\n(b) in vitro testing for IgE antibodies to Dermatophagoides farinae or\nDermatophagoides pteronyssinus house dust mites\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services Inc.\n3\na. Odactra will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Odactra therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of autom",
    "otwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class\n• Supply limits and/or Prior Authorization – Medical Necessity may be in place.\n4. References:\n1. Grastek® [package insert]. Blagrove,Swindon, Wiltshire, UK: Catalent Pharma Solutions\nLimited; September 2022.\n2. Oralair® [package insert]. Lenoir, NC: Greer Laboratories, Inc; September 2022.\n3. Ragwitek® [package insert]. Blagrove,Swindon, Wiltshire, UK: Catalent Pharma Solutions\nLimited; September 2022.\n4. Odactra® [package insert]. Blagrove,Swindon, Wiltshire, UK: Catalent Pharma Solutions\nLimited; May 2023.\n5. Cox, L, Nelson, H, Lockey, R, et al. Allergen immunotherapy: A practice parameter third\nupdate. American Academy of Allergy, Asthma & Immunology. December 2010.\n6. Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update.\nGreenhawt M, Oppenheimer J, Nelson M, et. al. Ann Allergy Asthma Immunol. 2017\nMar;118(3):276-282.e2.\nProgram Prior Authorization/Notification - SLIT\nChange Control\nDate Change\n5/2014 New\n5/2015 Administrative changes and references updated.\n4/2016 Administrative changes and references updated.\n4/2017 Added Odactra to criteria.\n3/2018 Annual review. References updated.\n3/2019 Annual review with administrative changes. Added statement regarding\nuse of automated processes and updated references.\n3/2020 Annual review. Updated references.\n3/2021 Annual review. Updated references.\n3/2022 Annual review. Updated references.\n3/2023 Annual review. Added state mandate language. Updated references.\n3/2024 Annual review. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n4\n3/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services Inc.\n5"
  ]
}